BetterLife Pharma Inc BETRF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BETRF is a good fit for your portfolio.
News
-
BetterLife Announces Closing of a Private Placement
-
BetterLife To Present BETR-001 Preclinical Data at the 2024 Conference of the Federation of European Neuroscience Societies (FENS) in Vienna, Austria
-
BetterLife Announces Closing of a Private Placement
-
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001
-
BetterLife Announces Intent to Complete Private Placement of Units
-
BetterLife Advances BETR-001 IND-enabling Studies
Trading Information
- Previous Close Price
- $0.10
- Day Range
- $0.10–0.11
- 52-Week Range
- $0.03–0.15
- Bid/Ask
- $0.10 / $0.11
- Market Cap
- $12.59 Mil
- Volume/Avg
- 36,086 / 25,090
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
Valuation
|
Metric
|
BETRF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BETRF
|
|---|---|
Quick Ratio | 0.07 |
Current Ratio | 0.12 |
Interest Coverage | −34.46 |
Quick Ratio
BETRF
Profitability
|
Metric
|
BETRF
|
|---|---|
Return on Assets (Normalized) | −538.24% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BETRF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Ggbzhbngxd | Gdcd | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Pjnrdszwn | Xcddgv | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Trzbxqkn | Cdtwrdl | $118.7 Bil | |||
| Moderna Inc
MRNA
| Qhdxnylh | Ttyq | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kwpxctb | Vykwml | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Vddlsmz | Jqsf | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Sdgkmwpc | Hlctq | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Zycsztsw | Ntbfxp | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Xfsyvpvzg | Rtmx | $15.0 Bil | |||
| Incyte Corp
INCY
| Dvfzbbvg | Zlwnvgd | $13.5 Bil |